ACEPODIA, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28 TWD | +0.54% |
|
-1.23% | -18.01% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | - | Sales 2023 | 16.59 534.54 1.38K | Capitalization | 19.33B 623B 1,613B |
|---|---|---|---|---|---|
| Net income 2022 | -1.41B -45.55B -118B | Net income 2023 | -817M -26.32B -68.18B | EV / Sales 2022 * | - |
| Net Debt 2022 | 3.01B 97B 251B | Net cash position 2023 | 6.02B 194B 502B | EV / Sales 2023 | 80,21,35,636 x |
| P/E ratio 2022 * |
-
| P/E ratio 2023 |
-23.7
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.54% | ||
| 1 week | -1.76% | ||
| Current month | -3.47% | ||
| 1 month | +1.64% | ||
| 3 months | -5.27% | ||
| 6 months | -10.59% | ||
| Current year | -18.45% |
1 week
27.50
28.70
1 month
27.4029.60
Current year
25.6034.65
1 year
25.6065.00
3 years
25.6065.00
5 years
25.6065.00
10 years
25.6065.00
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/24/17 | 28 | +0.54% | 509 965 |
| 16/24/16 | 27.85 | -0.54% | 1,277,034 |
| 15/24/15 | 28 | -0.36% | 433,452 |
| 14/24/14 | 28.1 | +1.26% | 486,258 |
| 13/24/13 | 27.75 | -2.63% | 1,120,960 |
End-of-day quote Taipei Exchange, May 16, 2024
More quotes
Acepodia Inc is engaged in the research and development of new anti-cancer drugs. The Company uses antibody-cell conjugation (ACC) and immune cells. The products include Gamma delta 2T cell platform including ACE1831 (ACE-gdT-CD20) an antibody linked to specific target CD20 for treatment of lymphoma, ACE2016 (ACE-gdT-EGFR) an antibody linked to specific target EGFR , the target treatment of EGFR+ solid tumors, such as lung cancer, ACE1708 (ACE-gdT-PDL1) an antibody linked to the specific target PDL1 antibody, the target treatment of solid tumors; off-the-shelf natural killer (oNK) cell platform including ACE1702 (ACE-oNK-HER2) linked to a specific target HER2 antibody, targeting treatment of HER2+ solid tumors, such as breast cancer. The technologies include antibody cell linking technology, Gamma delta 2T cell screening, culture and amplification technology, oNK cell culture and amplification technology, Acepodia series of new cell drug preparations freezing and thawing technology.
| 1st Jan change | Capi. | |
|---|---|---|
| -18.45% | 493M | |
| +33.37% | 50.85B | |
| +1.55% | 42.82B | |
| +50.07% | 42.03B | |
| -4.22% | 29.55B | |
| +11.57% | 26.11B | |
| -21.00% | 19.13B | |
| +7.36% | 13.05B | |
| +28.30% | 12.16B | |
| +23.80% | 12.08B |
- Stock Market
- Equities
- 6976 Stock
